At Lord’s Cricket Ground in the quiet, well-heeled streets of northwest London, different architectural eras collide together in a mishmash of mismatching styles representing the old and the new. A ...

Learn more about whether Harrow, Inc. or Ocular Therapeutix, Inc. is a better investment based on AAII's A+ Investor grades, ...

Learn more about whether Harrow, Inc. or Ligand Pharmaceuticals Incorporated is a better investment based on AAII's A+ ...

Please provide your email address to receive an email when new articles are posted on . Harrow plans to submit a new drug application in 2027 for sublingual MELT-300 for sedation and analgesia.

Harrow recently experienced a 24% share price increase over the last quarter, coinciding with its announcement of a $250 million debt financing via senior unsecured notes. This announcement comes at a ...

Harrow's recent debt refinancing, Melt Pharmaceuticals acquisition plans, and updated peak sales estimates reinforce the bullish thesis. Base case DCF modeling projects significant revenue growth ...

Harrow Inc (NASDAQ:HROW) reported a 45% increase in total revenue for the third quarter compared to the same period in 2024, reaching $71.6 million. The company is on track for a strong year of ...

Your support goes further this holiday season. When you buy an annual membership or give a one-time contribution, we’ll give a membership to someone who can’t afford access. It’s a simple way for you ...